""Enabling physicians to subclassify NSCLC tumors with miRview squamous based on FNA cell blocks, without the need for more invasive procedures, brings significant value to lung cancer patient management," noted Dr. Tina Edmonston, Director of Rosetta Genomics 'CLIA-certified laboratory."